Celldex Therapeutics, INC Schedule 13G passive stakes

Kynam Capital Management, LP, along with its GP and principal Yue Tang, has reported a 6.78% beneficial ownership of Celldex Therapeutics, Inc. common stock as of June 30, 2026.

T. Rowe Price Associates, Inc. has filed a Schedule 13G, reporting beneficial ownership of 6.0% of Celldex Therapeutics' common stock as of June 30, 2026.

Kynam Capital Management, LP has reported an 8.77% beneficial ownership stake in Celldex Therapeutics, Inc. via a Schedule 13G filing.

Bellevue Group AG and its subsidiary have filed an exit notice after reducing their stake in Celldex Therapeutics below the 5% reporting threshold.

State Street Corporation has reported beneficial ownership of 2,804,168 shares, representing 4.2% of the outstanding common stock of Celldex Therapeutics, as of March 31, 2026.

FMR LLC, through its affiliates, has reported beneficial ownership of 5.6% of Celldex Therapeutics Inc.'s common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.17% of Celldex Therapeutics' common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Celldex Therapeutics Inc. following an internal realignment.

State Street Corporation has reported a 5.1% beneficial ownership stake in Celldex Therapeutics Inc., holding 3,397,713 shares of common stock as of December 31, 2025.

Bellevue Group AG and its subsidiary Bellevue Asset Management AG have reported a 5.4% beneficial ownership stake in Celldex Therapeutics, Inc. common stock.

Commodore Capital LP and Commodore Capital Master LP have disclosed a beneficial ownership of 4.6% in Celldex Therapeutics, Inc. common stock as of September 30, 2025.

T. Rowe Price Associates, Inc. has reduced its beneficial ownership in Celldex Therapeutics Inc. to 3.6%, as disclosed in an amended Schedule 13G filing.

Wellington Management Group LLP and its affiliates have reported an 11.1% beneficial ownership stake in Celldex Therapeutics, Inc. common stock.

Eventide Asset Management and associated individuals have reported a 2.0% beneficial ownership stake in Celldex Therapeutics, Inc. as of June 30, 2025.

Wellington Management Group LLP and its affiliates have reported a beneficial ownership of 7.88% of Celldex Therapeutics, Inc.'s common stock.

Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen have jointly disclosed a beneficial ownership of 6.7% in Celldex Therapeutics, Inc., totaling 4,464,400 shares.

Kynam Capital Management, LP, along with its general partner and managing member, has disclosed a significant 9.79% beneficial ownership stake in Celldex Therapeutics, Inc.

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, disclosing a collective beneficial ownership of 12.6% of Celldex Therapeutics, Inc.'s common stock.

BlackRock, Inc. has filed an Amendment No. 4 to its Schedule 13G, revealing a 7.3% beneficial ownership stake in Celldex Therapeutics, Inc. as of March 31, 2025.

Commodore Capital LP and Commodore Capital Master LP have jointly disclosed a 5.0% beneficial ownership stake in Celldex Therapeutics, Inc. common stock.

Kynam Capital Management, LP, along with its affiliates, has reported a 7.63% beneficial ownership stake in Celldex Therapeutics, Inc., as detailed in a recent Schedule 13G filing.

T. Rowe Price Associates, Inc. has disclosed a 5.4% beneficial ownership stake in Celldex Therapeutics Inc., holding 3,557,136 shares of common stock as of December 31, 2024.

FMR LLC and its affiliates, along with Abigail P. Johnson, have reported a continued beneficial ownership of 7.3% of Celldex Therapeutics Inc.'s common stock as of December 31, 2024.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 8.3% in Celldex Therapeutics, Inc. as of December 31, 2024.